DoH Policies screened during the period: 1st July 2018 – 30th September 2018
Topics:
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).
Documents
- Equality Impact Assessment - Amendments to Article 77 of the Mental Health (Northern Ireland) Order 1986 – EQIA
- NICE Technology Appraisal TA521 - Guselkumab for treating moderate to severe plaque psoriasis
- NICE Technology Appraisal TA523 - Midostaurin for untreated acute myeloid leukaemia
- NICE Technology Appraisal TA524 - Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (review of TA446)
- NICE Technology Appraisal TA525 - Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
- NICE Technology Appraisal TA526 - Arsenic trioxide for treating acute promyelocytic leukaemia
- NICE Technology Appraisal TA527 - Beta interferons and glatiramer acetate for treating multiple sclerosis (review of TA32)
- NICE Technology Appraisal TA530 - Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
- NICE Technology Appraisal TA531 - Pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer (review of TA447)
- NICE Technology Appraisal TA532 - Cenegermin for treating neurotrophic keratitis
- NICE Technology Appraisal TA533 - Ocrelizumab for treating relapsing–remitting multiple sclerosis
- NICE Technology Appraisal TA534 - Dupilumab for treating moderate to severe atopic dermatitis
- NICE Technology Appraisal TA535 - Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
- NICE Technology Appraisal TA536 - Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
- NICE Technology Appraisal TA537 - Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE Technology Appraisal TA538 - Dinutuximab beta for treating neuroblastoma
- NICE Public Health Guideline NG90 - Physical activity and the environment
- NICE Public Health Guideline NG92 - Stop smoking interventions and services
- Consultation on regulations to restrict smoking in private vehicles carrying children
- Prohibiting the sale of nicotine inhaling products (NIPs), including e-cigarettes, to persons under the age of eighteen
- Health and Social Care Workforce Strategy
- Proposals to review Fees and Bursary Support for Individuals Training to become HSC Professionals